Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences Ltd has announced a collaboration with the NHS Southern Hub Research Team to evaluate its ColoSTAT® blood-based test for bowel cancer screening in England. This evaluation is a significant step towards the international commercialization of ColoSTAT®, which could enhance Rhythm’s market positioning by potentially reducing colorectal cancer mortality and healthcare costs.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on developing simple and affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes by detecting cancers at the earliest stages, thereby reducing the global cancer burden. Rhythm Biosciences collaborates with global partners to commercialize and distribute its diagnostic solutions.
Average Trading Volume: 334,254
Technical Sentiment Signal: Sell
Current Market Cap: A$26.62M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.